News

Once-daily orforglipron was more effective than placebo and just as safe as injectable GLP-1s in patients with diabetes and ...
This month: shorter recovery after TAVI, Down syndrome CV insights, the benefits of brisker walking, and more.
For all the different subpopulations, having a CAC score > 100 strongly predicted risk of CV death (P < 0.007). Yet the ...
Numerous components beyond length of sleep have important ties to cardiometabolic disease and related risk factors.
Added information from the assays could guide care, especially for intermediate-risk patients on the cusp of initiating ...
Juan Granada, MD, and Brian Lindman, MD, share insights on tools and data that can be used to ahieve earlier diagnosis and ...
The results show dose-dependent LDL-lowering and, in contrast to what was seen previously with VERVE-101, no safety issues.
There’s room on the market for new TAVI valves as long as they can compete with the best in practice, a researcher says.
The lack of effect on QoL and oxygen consumption help cement the idea that the disease isn’t the same as obstructive HCM.
The ABCVM wanted to certify cardiologists outside of ABIM, but the recent denial doesn’t mean their efforts have stopped.
Clinicians need to address maternal health at all stages, with some seeing a possible new role for GLP-1 drugs.
In patients with gastrointestinal cancers treated with fluoropyrimidine-based chemotherapy agents, better overall survival at 1 year offsets a small increase in their risk of CV events, new data ...